May 2016: The State of Psychiatry — Child Psychiatrists at APA Meeting 

Child psychiatrists at the annual meeting of the American Psychiatric Association in Atlanta, in May 2016, called for “big solutions to improving child mental health care,” recommending an aggressive drug algorithm approach for children. (Psychiatric News, June 16, 2016) This is a . . . Continue reading →

Fraudulent Science: What’s Retracted, What’s Not

17retraction-graphic-nyt.png

Even if retracted, published clinical trial reports that misrepresent findings, withhold negative data, or make false, or unsubstantiated claims have done irreparable damage. AHRP calls upon all medical journals to adopt a publication policy requiring submission of the sponsor’s formal Clinical Study Report to accompany articles about clinical trial findings. 

Continue reading →

Making a Killing–Marketing Exercises by Dr. Carl Elliott

The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research. Continue reading →

“Eli Lilly and the Case for the Corporate Death Penalty”

"The corporate death penalty may be appropriate in cases involving recidivist violators, corporations that are deemed to be incapable of reform (i.e. inherently criminogenic)…" Continue reading →

The Damaging Impact of PDUFA and Why It Should be Repealed

The re-prioritization of rapid approvals occurred at the expense of drug safety standards, Continue reading →

Activists Take on Eli Lilly Over Off-Label Marketing & Harm Caused by Zyprexa

The deceptive marketing of antipsychotic drugs has prompted new advocacy group to launch "The Just Say "Know" to Prescription Drugs Campaign."  Its goal is to get one million people to stop and reevaluate the medications they are taking. Continue reading →